3-62372510-A-C
Position:
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_018008.4(FEZF2):āc.359T>Gā(p.Val120Gly) variant causes a missense change. The variant allele was found at a frequency of 0.000244 in 1,338,566 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00016 ( 0 hom., cov: 33)
Exomes š: 0.00025 ( 0 hom. )
Consequence
FEZF2
NM_018008.4 missense
NM_018008.4 missense
Scores
1
3
15
Clinical Significance
Conservation
PhyloP100: 7.08
Genes affected
FEZF2 (HGNC:13506): (FEZ family zinc finger 2) Predicted to enable transcription cis-regulatory region binding activity. Predicted to be involved in positive regulation of transcription, DNA-templated. Predicted to act upstream of or within several processes, including negative regulation of transcription by RNA polymerase II; nervous system development; and regulation of neuron differentiation. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -8 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.0661107).
BS2
High AC in GnomAd4 at 24 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FEZF2 | NM_018008.4 | c.359T>G | p.Val120Gly | missense_variant | 2/5 | ENST00000283268.8 | NP_060478.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FEZF2 | ENST00000283268.8 | c.359T>G | p.Val120Gly | missense_variant | 2/5 | 1 | NM_018008.4 | ENSP00000283268.3 | ||
FEZF2 | ENST00000475839.1 | c.359T>G | p.Val120Gly | missense_variant | 1/4 | 1 | ENSP00000418804.1 | |||
FEZF2 | ENST00000486811.5 | c.359T>G | p.Val120Gly | missense_variant | 3/6 | 5 | ENSP00000418589.1 |
Frequencies
GnomAD3 genomes AF: 0.000160 AC: 24AN: 150258Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
24
AN:
150258
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000123 AC: 7AN: 56684Hom.: 0 AF XY: 0.000151 AC XY: 5AN XY: 33020
GnomAD3 exomes
AF:
AC:
7
AN:
56684
Hom.:
AF XY:
AC XY:
5
AN XY:
33020
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000254 AC: 302AN: 1188208Hom.: 0 Cov.: 31 AF XY: 0.000253 AC XY: 146AN XY: 576532
GnomAD4 exome
AF:
AC:
302
AN:
1188208
Hom.:
Cov.:
31
AF XY:
AC XY:
146
AN XY:
576532
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000160 AC: 24AN: 150358Hom.: 0 Cov.: 33 AF XY: 0.000163 AC XY: 12AN XY: 73466
GnomAD4 genome
AF:
AC:
24
AN:
150358
Hom.:
Cov.:
33
AF XY:
AC XY:
12
AN XY:
73466
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
7
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 06, 2022 | The c.359T>G (p.V120G) alteration is located in exon 2 (coding exon 1) of the FEZF2 gene. This alteration results from a T to G substitution at nucleotide position 359, causing the valine (V) at amino acid position 120 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T;T;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
.;.;T
M_CAP
Benign
D
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
L;L;L
PrimateAI
Pathogenic
D
PROVEAN
Benign
N;N;N
REVEL
Benign
Sift
Uncertain
D;D;D
Sift4G
Uncertain
D;D;D
Polyphen
B;B;B
Vest4
MutPred
Gain of glycosylation at P119 (P = 0.0961);Gain of glycosylation at P119 (P = 0.0961);Gain of glycosylation at P119 (P = 0.0961);
MVP
MPC
1.4
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at